Numinus Wellness Inc. announced the appointment of three key advisors to its new Bioscience Advisory Board. The following advisors have been appointed: Mr. Pechenik is a registered patent attorney and the founder of Calyx Law. Mr. Pechenik started Calyx Law to help cannabis and psychedelics ventures design and implement their IP strategies.

Mr. Pechenik also contributes to Psilocybin Alpha as editor-at- large, writing about psychedelics IP and contributing to psychedelics patent, legalization, and decriminalization trackers, and is a member of Chacruna's Council for the Protection of Sacred Plants. Dr. Spagnuolo is a past member of the Natural Health Products Research Society of Canada and has received funding from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC). Dr. Spagnuolo's research focuses on understanding the therapeutic potential of nutraceuticals (i.e. foods that provide medical or health benefits) and has included investigation of anti-cancer effects in certain compounds.

He is experienced in developing novel, multidisciplinary techniques that combine drug discovery platforms traditionally used in the pharmaceutical industry with new areas of study. Dr. Cory Harris involves collaboration with Inuit and First Nations communities, and projects have included investigating the ethical and evidence-based use of alternative medicines and the health benefits and risks of wild plant foods. Dr. Harris also heads a graduate research community that undertakes special interest projects, operating out of UOttawa and supported by NSERC, Mitacs and the Province of Ontario.

The new Bioscience Advisory Board will contribute strategically to advancing Numinus' IP strategy, including product development and clinical trial activities out of the Company's Health Canada-licensed research facility, Numinus Bioscience. It joins Numinus' existing General and Clinical advisory boards, comprised of leading industry and subject-matter experts who have been selected to support corporate and therapeutic protocol development. Among them are Drs.

Gabor Maté, Dennis McKenna and Zachary Walsh.